The African Centre for Disease Control and Prevention (Africa CDC) has expressed its concern over the rise in Mpox cases (formerly known as monkeypox) in Africa.
In an update released last Friday on the Mpox outbreak in Africa, the director general of Africa CDC, Jean Kaseya, stated that the continent is facing limited diagnostic capacities and other challenges related to the rapid spread of the disease in new countries, as well as disparate attempts to combat Mpox, while greater coordination of efforts would be necessary.
Data from the Africa CDC suggests that between the beginning of 2024 and August 23, a total of 21,466 potential cases of Mpox and 591 deaths have been reported in 13 member countries of the African Union (AU).
The 13 AU members that have reported cases of monkeypox to date are: Burundi, Cameroon, the Central African Republic, the Republic of Congo, Côte d’Ivoire, the Democratic Republic of the Congo (DRC), Gabon, Liberia, Kenya, Nigeria, Rwanda, South Africa, and Uganda.
“The cases and deaths observed are just the tip of the iceberg, given that monkeypox is most often a mild condition and that surveillance, testing, contact tracing, and reporting are limited,” Mr. Kaseya stated in a newsletter addressed to African health ministers regarding the current monkeypox outbreak in Africa.
He also warned about the high fatality rate of the disease, which he said generally ranges between 3% and 4%, adding that the link between the disease and HIV is particularly concerning for Africa.
MG/gik/lb/te/APA
Increasing Concerns Over Mpox in Africa: Future Trends and Implications
The Africa CDC has raised alarms regarding the rising incidence of Mpox, previously known as monkeypox, across the continent. As cases surge in 13 African Union member states, the limited diagnostic capacities and fragmented response efforts highlight key areas requiring urgent attention.
Between January 2024 and August 23, 2024, the Africa CDC reported a staggering 21,466 potential Mpox cases and 591 deaths. This spike underscores the growing public health challenge faced by these nations, where officials like Jean Kaseya emphasize that the current reported figures may only represent a fraction of the reality. The disease, often mild but with concerning fatality rates of 3% to 4%, presents an urgent need for enhanced surveillance and better healthcare infrastructures.
Looking ahead, several trends are anticipated. Firstly, the need for improved diagnostic capabilities will become paramount. Countries struggling with limited resources must prioritize the establishment of robust testing frameworks to ensure accurate data collection and effective response measures. This transformation may also encourage international partnerships aimed at bolstering healthcare systems across the continent.
Moreover, the troubling link between Mpox and HIV, particularly in regions with high prevalence, necessitates a focused approach. Health strategies may evolve to integrate Mpox prevention within the broader context of HIV/AIDS care, enabling a more comprehensive response to dual health threats.
The current crisis may also lead to increased public awareness initiatives about Mpox, encouraging communities to recognize symptoms early and seek medical assistance promptly. Education campaigns can play a significant role in mitigating the impact of Mpox, particularly in areas where misinformation may hinder effective health-seeking behavior.
As Mpox continues to challenge public health in Africa, the call for coordinated efforts among nations and international organizations will remain critical. Collaborative frameworks can foster knowledge sharing, resource allocation, and strategic planning to better manage this emerging health crisis and protect vulnerable populations.